MEETINGS & COURSES
Find a meeting

 FEATURED MEETINGS
  Rome 2010
  Kiawah Eye 2010
  OSN New York 2010
  Hawaiian Eye 2011
  Retina 2011
 
Breaking Influenza
A (H1N1) Updates
OCULAR SURGERY NEWS EUROPE EDITION November 1, 2009
Swollen lids, pain, opaque vitreous linked with proven endophthalmitis
ESCRS endophthalmitis study data suggest patients with streptococcal infections had worse visual outcomes than those with staphylococcal infections.
Submit a Comment Submit a Comment Print  Print Email this page to a friend  E-mail
Peter Barry, FRCS
Peter Barry

Swollen lids, pain and opaque vitreous were strongly associated with confirmed endophthalmitis after cataract surgery, according to an analysis of data from the European Society of Cataract and Refractive Surgeons endophthalmitis study.

In addition, patients with streptococcal infections had strikingly worse visual outcomes and showed an earlier onset of disease than those with staphylococcal infections.

The study previously reported that intracameral injection of 1 mg of cefuroxime yielded an almost fivefold reduction in the rate of postoperative endophthalmitis compared with patient groups that did not receive the antibiotic.

“The most significant finding of the ESCRS endophthalmitis study was that the direct injection of 1 mg of cefuroxime in 0.1 mL of normal saline into the anterior chamber at the end of the case reduced the incidence of endophthalmitis by a factor of five compared to the control study group who received povidone iodine alone and no perioperative antibiotics topically or intracamerally,” Peter Barry, FRCS, the corresponding author, told Ocular Surgery News in an e-mail interview.

The ESCRS study produced similar results to other analyses, such as the Endophthalmitis Vitrectomy Study conducted in the U.S. from 1990 to 1994. For example, a majority of patients in both studies presented with endophthalmitis within 7 days after cataract surgery. Additionally, streptococcal infection showed earlier onset and led to worse visual outcomes than staphylococcal infection in both studies.

Results of the most recent analysis are published in the Journal of Cataract and Refractive Surgery.

The study

The ESCRS study included 16,211 patients, the largest series of patients evaluated for evidence-based prophylaxis of endophthalmitis after cataract surgery in a randomized clinical trial; 8,108 patients received intracameral cefuroxime injections and 8,103 did not receive them.

One group was a control that received a perioperative placebo drop regimen. A second group received a perioperative drop regimen of levofloxacin 0.5%. A third group received an intracameral injection of 1 mg cefuroxime in addition to the placebo. A fourth group received intracameral cefuroxime in addition to the topical levofloxacin.

“Intensive perioperative antibiotic drops, in this study levofloxacin, were not shown to be of benefit,” Dr. Barry said.

All groups received a standard postoperative regimen of topical levofloxacin 0.5%, one drop four times daily, for at least 1 week to prevent wound infection.

Twenty-nine patients presented with postoperative endophthalmitis. Among the 29 endophthalmitis cases, 20 cases were proven and nine were unproven.

Streptococcal, staphylococcal infections

The median interval to presentation with signs and symptoms was 4.5 days in proven cases and 9 days in unproven cases; the median interval was 5 days. A larger portion of proven cases took place within 7 days after surgery.

After performing multivariable logistic regression modeling, investigators found a strong relationship between proven cases of endophthalmitis and swollen lids (P = .04) and opaque vitreous (P = .05).

Eight cases caused by streptococcal infection correlated with pain, hypopyon, chemotic conjunctiva and clear corneal incisions.

Visual outcomes varied between eyes with streptococcal and staphylococcal infections; outcomes were significantly worse in streptococcal cases.

“Although postoperative visual acuities were not statistically tested, the difference in visual outcome between cases of streptococcal and cases of staphylococcal infections were striking,” Dr. Barry said.

Final postoperative visual acuity among 11 staphylococcal cases ranged from 20/20 to 20/80, with no patients deemed legally blind. Three of the 11 cases received intracameral cefuroxime.

Final visual acuity among eight streptococcal cases ranged from 20/20 to no light perception; five patients were deemed legally blind because of streptococci.

None of the eight streptococcal cases received intracameral cefuroxime. – by Matt Hasson

Reference:

  • Barry P, Gardner S, Seal D, ESCRS Endophthalmitis Study Group, et al. Clinical observations associated with proven and unproven cases in the ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. J Cataract Refract Surg. 2009;35(9):1523-1531.

  • Peter Barry, FRCS, can be reached at Royal Victoria Eye Ear Hospital, The Eye Clinic, 33 Herbert Ave., Merrion Road, Dublin 4, Ireland; +353-1-283-7203; e-mail: peterbarryfrcs@eircom.net.

The OSN SuperSite is intended for physician use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will the OSN SuperSite be used for medical advice to patients.

There are no comments for this article. Be the first to comment.

Your comment

Name:
Comments:
SEE ALSO
Anterior chamber depth can play significant role in phaco
OCULAR SURGERY NEWS U.S. EDITION February 25, 2010
Younger cataract patients report better vision than older patients at 10 years postop
Posted on the OSN SuperSite February 8, 2010
Phaco surgery may still pose risk for progression of diabetic retinopathy
OCULAR SURGERY NEWS ASIA-PACIFIC EDITION February 1, 2010
Ozurdex injection technique
Ozurdex injection technique

Submitted by: Allergan; Sunil Gupta, MD (2/4/2010).

Endothelial keratoplasty challenges the primacy of full-thickness transplantation
Corneal transplantation has long been the preferred treatment for pathologies that respond poorly to topical medications or implants.